Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04764383 (ClinicalTrials.gov)	January 1, 2022	18/2/2021	Histaminergic Basis of Fatigue in Multiple Sclerosis	Histaminergic Basis of Fatigue in Multiple Sclerosis	Multiple Sclerosis	Drug: L-Histidine;Drug: Placebo;Drug: Lodosyn	University of Miami	NULL	Withdrawn	18 Years	60 Years	All	0	Phase 2	United States
2	NCT03266965 (ClinicalTrials.gov)	March 23, 2018	4/7/2017	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Multiple Sclerosis	Drug: Carbidopa;Dietary Supplement: L-Histidine	University of Miami	United States Department of Defense	Completed	18 Years	60 Years	All	18	Phase 1	United States